Pancreatic Cancer Research

ResearcherUniversity of California San DiegoActive in the last 2 years

Kentaro Miyake

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4680-4317; OpenAlex author ID A5084841997. Sources: OpenAlex.

Their work

Papers
26 (first author 10, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2017: 3 papers · 2018: 8 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 7 papers · 2026: 1 paper

Papers 26

  1. High CDCP1 Expression Reflects Immune and Stromal Remodeling and Oncogenic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.14740/wjon2682↗
  2. Novel machine-learning model for predicting lymph node metastasis in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12836↗
  3. Methionine restriction inhibits pancreatic cancer proliferation while suppressing JAK2/STAT3 pathway. First author DOI 10.1016/j.pan.2024.11.023↗
  4. Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study). Co-author DOI 10.1038/s41598-025-23608-5↗
  5. Clinical Relevance of High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transection Margin in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-17400-y↗
  6. ASO Author Reflections: A New Proposal for Therapeutic Strategies in Patients with High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transectio… Co-author DOI 10.1245/s10434-025-17508-1↗
  7. Prognostic Significance of Post-Neoadjuvant Chemotherapy Carbohydrate Antigen 19-9 Levels in Patients With Resectable Pancreatic Cancer Treated With S-1 and Ge… First author DOI 10.14740/wjon2563↗
  8. Neoadjuvant Chemoradiotherapy Enhances Tumor PD-L1 Expression in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17554↗
  9. SLC7A11 and the glutathione pathway as novel prognostic markers in resectable pancreatic ductal adenocarcinoma: A metabolomics study of clinical specimens. First author DOI 10.1016/j.pan.2024.05.530↗
  10. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.1245↗
  11. High Incidence of Lymph-node Metastasis in a Pancreatic-cancer Patient-derived Orthotopic Xenograft (PDOX) NOG-Mouse Model. First author DOI 10.21873/anticanres.15532↗
  12. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemorad… Co-author DOI 10.1002/jhbp.883↗
  13. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse… First author DOI 10.1016/j.canlet.2020.07.034↗
  14. Efficacy of prolonged elemental diet therapy after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A pilot prospective randomized trial (UMIN0000… Co-author DOI 10.1016/j.clnesp.2019.07.017↗
  15. Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy. First author DOI 10.21873/anticanres.13726↗
  16. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Can… Co-author DOI 10.1002/jcb.26224↗
  17. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. First author DOI 10.1016/j.canlet.2018.06.016↗
  18. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Co-author DOI 10.1016/j.tice.2018.05.003↗
  19. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived… First author DOI 10.1080/15384101.2018.1445907↗
  20. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopi… First author DOI 10.1080/15384101.2018.1480223↗
  21. Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore. Co-author DOI 10.1245/s10434-018-6344-6↗
  22. Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse … Co-author DOI 10.18632/oncotarget.24264↗
  23. Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model. First author DOI 10.18632/oncotarget.26484↗
  24. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility co… Co-author DOI 10.1002/jso.24681↗
  25. MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy. Co-author DOI 10.1016/j.jss.2017.07.003↗
  26. Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer or… Co-author DOI 10.1080/15384101.2017.1315489↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Itaru Endo · 17 shared papers, 2017–2026 · strength 3.05
  2. Yuki Homma · 12 shared papers, 2017–2026 · strength 2.01
  3. Yasuhiro Yabushita · 6 shared papers, 2023–2025 · strength 1.44
  4. Robert M. Hoffman · 13 shared papers, 2017–2022 · strength 1.02
  5. Michael Bouvet · 12 shared papers, 2017–2022 · strength 0.96
  6. Takashi Murakami · 9 shared papers, 2017–2025 · strength 0.86
  7. Jun Yamamoto · 3 shared papers, 2020–2026 · strength 0.66
  8. Kei Kawaguchi · 7 shared papers, 2018–2022 · strength 0.59
  9. Michiaki Unno · 7 shared papers, 2018–2022 · strength 0.59
  10. Yukihiko Hiroshima · 5 shared papers, 2017–2025 · strength 0.56
  11. Masanori Oshi · 2 shared papers, 2024–2026 · strength 0.52
  12. Kei Kobayashi · 2 shared papers, 2025 · strength 0.49
  13. Hiroki Ohya · 2 shared papers, 2024–2025 · strength 0.47
  14. Ryutaro Mori · 3 shared papers, 2018–2025 · strength 0.37
  15. Thinzar Min Lwin · 5 shared papers, 2017–2018 · strength 0.36
  16. Yasushi Ichikawa · 3 shared papers, 2017–2025 · strength 0.34
  17. Norihiko Sugisawa · 3 shared papers, 2019–2022 · strength 0.34
  18. Kanechika Den · 2 shared papers, 2017–2025 · strength 0.30
  19. Manabu Maebashi · 1 shared paper, 2025 · strength 0.28
  20. Susumu Daibo · 1 shared paper, 2025 · strength 0.25
  21. Eriko Katsuta · 1 shared paper, 2025 · strength 0.22
  22. Kensuke Kubota · 1 shared paper, 2025 · strength 0.22
  23. Noritoshi Kobayashi · 1 shared paper, 2025 · strength 0.22
  24. Ho Kyoung Hwang · 3 shared papers, 2017–2018 · strength 0.19
  25. Sant P. Chawla · 2 shared papers, 2019–2020 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.